Abiopharma

COVALON TECHNOLOGIES LTD. (CVALF)

Symbol	CVALF
Name	COVALON TECHNOLOGIES LTD.
Sector	UNDEFINED
Region	North America
Industry	-
Address	L4W 5S7 Canada ON 1660 Tech Avenue, Unit 5
Telephone	+1 905-568-8400
Fax	—
Email	—
Website	http://www.covalon.com
Incorporation	CA
Incorporated On	2004
Employees	—
Fiscal Year	9/30
Public Since	—
Exchanges	OTC
Auditor	PricewaterhouseCoopers LLP;
Audit Status	AUDITED
Reporting Status	International Reporting: TSX Venture Exchange
CIK	0001308964
Description	Covalon Technologies Ltd. is a research-driven developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives, specializing in advanced wound care, infection prevention, and surgical solutions. We leverage our proprietary medical technology platforms and expertise in two key ways: developing and marketing innovative medical solutions under the Covalon brand and collaborating with other medical companies to develop and commercialize products through licensing and development agreements. Additional info from OTC: Covalon Technologies Ltd. is a research-driven developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives, specializing in advanced wound care, infection prevention, and surgical solutions. We leverage our proprietary medical technology platforms and expertise in two key ways: developing and marketing innovative medical solutions under the Covalon brand and collaborating with other medical companies to develop and commercialize products through licensing and development agreements.

2026-06-09 17:00

Covalon Announces Appointment of New Director and DSU Grants

2026-05-21 11:00

Covalon Reports 2026 Second Quarter Results

2026-05-14 17:00

Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results

2026-04-15 21:30

Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care

2026-03-27 21:03

Covalon Announces Grant of Deferred Share Units

2026-03-26 11:00

Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders

2026-03-18 11:00

Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026

2026-02-25 12:00

Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights

2026-02-19 21:15

Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications

2026-02-19 12:00

Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results